Search

Author/Creator Pant, S

1. 1130OResponses and durability of clinical benefit in renal cell carcinoma treated with pegilodecakin in combination with anti-PD-1 inhibitors. (23rd October 2018)

Authors:
Tannir, N M; Naing, A; Papadopoulos, K P; Wong, D J; Korn, W M; Aljumaily, R; Autio, K A; Pant, S; Bauer, T M; Drakaki, A; Daver, N; Hung, A; Oft, M; Leveque, J
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 1143PResponses and durability of clinical benefit in pancreatic ductal adenocarcinoma (PDAC) patients treated with pegilodecakin (AM0010) in combination with 5-FU/LV and oxaliplatin (FOLFOX). (23rd October 2018)

Authors:
Hecht, J R; Naing, A; Falchook, G S; Patel, M R; Aljumaily, R; Wong, D J; Autio, K A; Wainberg, Z A; Javle, M; Bendell, J; Pant, S; Hung, A; Oft, M; Leveque, J; Papadopoulos, K P
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. SO-008Ramucirumab plus merestinib in previously treated metastatic colorectal cancer: safety, pharmacokinetic, and preliminary efficacy findings from a Phase 1 study. (2nd July 2019)

Authors:
Saleh, M; Cassier, P; Eberst, L; Naik, G; II, V Morris; Pant, S; Terret, C; Gao, L; Long, A; Mao, H; McNeely, S; Carlesi, R; Fu, S
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 4
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗